Related Experiment Video
Updated: Mar 14, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Targeted Degradation of Dipeptidyl Peptidase-4 via Proteolysis-Targeting Chimera Technology for Sustained Glycemic
ZiYi Wang1,2, SiJia Lin1,2, Xue Dong1,2
1Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China.
Abstract:
Dipeptidyl peptidase-4 (DPP-4), a key regulator of glucose metabolism that cleaves glucagon-like peptide-1 (GLP-1), is a critical therapeutic target for type 2 diabetes. Conventional DPP-4 inhibitors like alogliptin act through competitive active-site inhibition, requiring sustained exposure, which can lead to resistance and off-target effects. Here, we leveraged proteolysis-targeting chimera (PROTAC) technology to develop a heterobifunctional DPP-4 degrader. The PROTAC (DeDPP4) was synthesized by conjugating alogliptin, a high-affinity DPP-4 ligand, with a cereblon (CRBN)-recruiting E3 ubiquitin ligase ligand. The DeDPP4 demonstrated a dose-dependent DPP-4 depletion effect in A549 cells, with a maximal degradation rate of >80%. In an in vivo experiment, a single administration of the DeDPP4 (10 mg/kg) elicited prolonged glycemic control, maintaining reduced blood glucose levels over 60 h, which was 5 times that of alogliptin. The DeDPP4 induced sustained GLP-1 elevation and enhanced glucose tolerance, correlating with DPP-4 degradation in liver and adipose tissues.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

